- Home
- NKTX vs SLS Comparison
NKTX vs SLS Comparison
Compare NKTX & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- SLS
- Stock Information
- Founded
- NKTX 2015
- SLS 2012
- Country
- NKTX United States
- SLS United States
- Employees
- NKTX N/A
- SLS N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- SLS Health Care
- Exchange
- NKTX Nasdaq
- SLS Nasdaq
- Market Cap
- NKTX 123.5M
- SLS 169.6M
- IPO Year
- NKTX 2020
- SLS N/A
- Fundamental
- Price
- NKTX $1.74
- SLS $1.71
- Analyst Decision
- NKTX Strong Buy
- SLS
- Analyst Count
- NKTX 6
- SLS 0
- Target Price
- NKTX $14.80
- SLS N/A
- AVG Volume (30 Days)
- NKTX 422.6K
- SLS 3.0M
- Earning Date
- NKTX 05-14-2025
- SLS 05-13-2025
- Dividend Yield
- NKTX N/A
- SLS N/A
- EPS Growth
- NKTX N/A
- SLS N/A
- EPS
- NKTX N/A
- SLS N/A
- Revenue
- NKTX N/A
- SLS N/A
- Revenue This Year
- NKTX N/A
- SLS N/A
- Revenue Next Year
- NKTX N/A
- SLS N/A
- P/E Ratio
- NKTX N/A
- SLS N/A
- Revenue Growth
- NKTX N/A
- SLS N/A
- 52 Week Low
- NKTX $1.31
- SLS $0.77
- 52 Week High
- NKTX $8.23
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- NKTX 45.11
- SLS 54.26
- Support Level
- NKTX $1.70
- SLS $1.36
- Resistance Level
- NKTX $1.82
- SLS $2.12
- Average True Range (ATR)
- NKTX 0.10
- SLS 0.18
- MACD
- NKTX -0.01
- SLS -0.01
- Stochastic Oscillator
- NKTX 18.82
- SLS 46.05
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.